1. Home
  2. MSN vs BIVI Comparison

MSN vs BIVI Comparison

Compare MSN & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Emerson Radio Corporation

MSN

Emerson Radio Corporation

HOLD

Current Price

$0.36

Market Cap

8.2M

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.16

Market Cap

9.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSN
BIVI
Founded
1948
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
9.2M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
MSN
BIVI
Price
$0.36
$1.16
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
107.0K
102.4K
Earning Date
02-13-2026
02-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$8,739,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.28
$1.10
52 Week High
$0.85
$20.40

Technical Indicators

Market Signals
Indicator
MSN
BIVI
Relative Strength Index (RSI) 42.16 41.67
Support Level $0.36 $1.11
Resistance Level $0.39 $1.29
Average True Range (ATR) 0.02 0.08
MACD -0.00 0.00
Stochastic Oscillator 0.70 26.32

Price Performance

Historical Comparison
MSN
BIVI

About MSN Emerson Radio Corporation

Emerson Radio Corp operates in the consumer electronics industry. The company designs, sources, imports, and markets a variety of houseware and consumer electronic products, and licenses the Emerson trademark domestically and internationally. The products offered by the company are televisions, digital versatile disc players and video cassette recorders, audio accessories, microwave ovens, home theatres, high-end audio products, office products, mobile stereo, and wireless products.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: